Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Roszik

Showing results (151-160 of 166) with videos related to

Pageof 17
Sort By:
BMC Medicine|October 26, 2016
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation setJason Roszik, Lauren E Haydu, Kenneth R Hess, et al.
Journal for Immunotherapy of Cancer|July 10, 2021
Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutationsFenge Li, Ligang Deng, Kyle R Jackson, et al.
Gastroenterology|March 22, 2021
Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal CancerAkira Inoue, Frederick S Robinson, Rosalba Minelli, et al.
JAMA Oncology|April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical TrialGuo Chen, Jennifer L McQuade, David J Panka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, et al.
Cell Metabolism|April 10, 2018
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell TherapyTina Cascone, Jodi A McKenzie, Rina M Mbofung, et al.
The Journal of Investigative Dermatology|August 23, 2014
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanomaAlan E Siroy, Genevieve M Boland, Denái R Milton, et al.
Cell Systems|October 1, 2018
A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β SuperfamilyAnil Korkut, Sobia Zaidi, Rupa S Kanchi, et al.
Science Translational Medicine|March 3, 2017
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistanceWhijae Roh, Pei-Ling Chen, Alexandre Reuben, et al.
Cancer Discovery|December 10, 2015
Loss of PTEN Promotes Resistance to T Cell-Mediated ImmunotherapyWeiyi Peng, Jie Qing Chen, Chengwen Liu, et al.
Pageof 17

Showing results (151-160 of 166) with videos related to

Sort By:
Pageof 17
BMC Medicine|October 26, 2016
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation setJason Roszik, Lauren E Haydu, Kenneth R Hess, et al.
Journal for Immunotherapy of Cancer|July 10, 2021
Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutationsFenge Li, Ligang Deng, Kyle R Jackson, et al.
Gastroenterology|March 22, 2021
Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal CancerAkira Inoue, Frederick S Robinson, Rosalba Minelli, et al.
JAMA Oncology|April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical TrialGuo Chen, Jennifer L McQuade, David J Panka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2023
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, et al.
Cell Metabolism|April 10, 2018
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell TherapyTina Cascone, Jodi A McKenzie, Rina M Mbofung, et al.
The Journal of Investigative Dermatology|August 23, 2014
Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanomaAlan E Siroy, Genevieve M Boland, Denái R Milton, et al.
Cell Systems|October 1, 2018
A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β SuperfamilyAnil Korkut, Sobia Zaidi, Rupa S Kanchi, et al.
Science Translational Medicine|March 3, 2017
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistanceWhijae Roh, Pei-Ling Chen, Alexandre Reuben, et al.
Cancer Discovery|December 10, 2015
Loss of PTEN Promotes Resistance to T Cell-Mediated ImmunotherapyWeiyi Peng, Jie Qing Chen, Chengwen Liu, et al.
Pageof 17